Navigation Links
Moody's Upgrades Mylan
Date:5/23/2012

Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the impacts of competition; changes in economic and financial conditions of the company's business; uncertainties and matters beyond the control of management; and the other risks detailed in the company's filings with the Securities and Exchange Commission.  The company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service a habit, do what's right, not what's easy and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately one-third of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 150 countries and territories. Our workforce of more than 18,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com

 


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. HIPAA 5010 Ready: DST Health Solutions Launches Upgrades of Amisys Advance, PowerMHS, PowerMHC and PowerSTEPP
2. Mylan Confirms First-to-File Patent Challenge Relating to Lescol(R)
3. Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008
4. Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
5. Shire Receives FOSRENOL Paragraph IV Notice Letters from Barr Laboratories and Mylan
6. Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008
7. Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patent
8. Mylan Confirms Four First-to-File Challenges
9. Mylans Matrix Receives First Tentative FDA Approval Under PEPFAR for Generic Truvada(R)
10. Mylans Matrix Selected by the Clinton HIV/AIDS Initiative and UNITAID as the Primary Supplier of Five Second-Line and Seven Pediatric HIV/AIDS Treatments
11. Mylan Receives Tentative FDA Approval for Generic Version of Singulair(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sep. 02, 2015 ... the addition of Jain PharmaBiotech,s new report "Gene ... offering. The markets for gene therapy are ... gene therapy product and it is marketed in ... are estimated for the years 2014-2024. The estimates are ...
(Date:9/2/2015)... September 2, 2015 Biovista Inc. ... of the 2015 BeHEARD science challenge, a global competition ... disease researchers, access to the latest life science innovations ... repositioning and pathway analytics capability to support Steven ... in the study of Niemann-Pick Disease Type A (NPA), ...
(Date:9/2/2015)... , Sept. 2, 2015  Neurotech Pharmaceuticals, ... enrolled in the multicenter Phase 2 clinical trial ... long-term treatment of recurrent subfoveal choroidal neovascularization secondary ... is a unique vascular endothelial growth factor (VEGF) ... implant. "This landmark proof-of-concept study will ...
(Date:9/2/2015)... -- Aytu BioScience, Inc. (OTCQB: AYTU), a specialty healthcare ... conditions, announced today that it has closed the final ... raising a total of $5.175 million, which includes proceeds ... Josh Disbrow , Chief Executive Officer of ... to be used to conduct clinical studies for both ...
Breaking Biology Technology:Global Gene Therapy Market Study 2015-2024 - Technologies, Markets and Companies Analysis 2Biovista Sponsors Wylder Nation Foundation's Research on Acid Sphingomyelinase Deficiency 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4Aytu BioScience Completes $5.175 Million Private Placement 2Aytu BioScience Completes $5.175 Million Private Placement 3
... Sky One,Medical, Inc. ("China Sky One Medical" or ... integrated pharmaceutical company producing over-the-counter,drugs in the People,s ... production at Peng Lai Jin Chuang Company ("Jin ... 14, 2008., Jin Chuang, a subsidiary of ...
... (Nasdaq: NLTX ), today announced interim data from its ... natriuretic,peptide, in patients hospitalized for acute heart failure., ... pressure -- Statistically significant ... right atrial pressure -- Trend toward increase in ...
... Va., Oct. 14 Insmed Inc. (Nasdaq,CM: INSM), a ... will seek shareholder approval to implement a reverse,stock split, ... November,24, 2008, in an effort to meet the minimum ... Market., On September 3, 2008, the Company announced ...
Cached Biology Technology:China Sky One Medical, Inc. Starts Production at Newly Acquired Facility and Reaffirms Guidance 2China Sky One Medical, Inc. Starts Production at Newly Acquired Facility and Reaffirms Guidance 3Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure 2Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure 3Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure 4Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure 5Insmed to Seek Shareholder Approval for Reverse Split 2Insmed to Seek Shareholder Approval for Reverse Split 3
(Date:8/12/2015)... Florida , August 12, 2015 ... pace of mobile payment innovation and advanced biometrics technology ... replace the way consumers rely on using their credit ... with reinventing the future for payment services led by ... NXTD ), :  Google, Inc. (NASDAQ: GOOG ...
(Date:8/11/2015)... 2015 Today, ZUK announced its Android smartphone ... as expected revenues in 2015 that relate to sales of FPC1155 ... of approximately 2,200 MSEK for 2015. Jörgen Lantto, CEO ... prominent smartphone manufacturer in China ... FPC1 155 for Z1 , ...
(Date:8/6/2015)... , Aug. 6, 2015  Today, U.S. ... visit Crossmatch ™ to learn firsthand how ... protect data. Crossmatch is a world leader in ... and expertise are helping federal agencies and commercial ... security.   "The vast majority of ...
Breaking Biology News(10 mins):Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2Rep. Honda to Visit Crossmatch in Redwood City 2
... food safety is a good thing. As consumers, we ... above and beyond food safety mandates to ensure that ... or viruses that can make us sick. , But ... cutting into the last corners of wildlife habitat and ...
... A new study led by researchers from Harvard School ... Institute in the UK has, for the first time, ... a bacterial population following the introduction of a vaccine. ... changed following the introduction of the ,Prevnar, conjugate polysaccharide ...
... contains trillions of cells, all derived from a single cell, or ... That single cell contains all the genetic information needed to develop ... each new cell as it divides into the many diverse types ... being. If each cell is genetically identical, however, how ...
Cached Biology News:Zeal to ensure clean leafy greens takes bite out of riverside habitat in California 2Zeal to ensure clean leafy greens takes bite out of riverside habitat in California 3Genome sequencing provides unprecedented insight into causes of pneumococcal disease 2Divide and define: Clues to understanding how stem cells produce different kinds of cells 2Divide and define: Clues to understanding how stem cells produce different kinds of cells 3
Rabbit polyclonal to Survivin DEx3 ( Abpromise for all tested applications). entrezGeneID: 332 SwissProtID: O15392...
Ezrin/Radixin/Moesin Antibody...
Rabbit Anti-conjugated Agmatine Polyclonal Antibody...
ABCA1 Immunogen: Mouse ABCA1-expressing HeLa stable transfectants. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: